Markets Screener Institutions Status About FAQ Insights API

Loading institutional data...

Request data / API access →

Data from SEC EDGAR filings: company financials and 13F holdings.

Disclaimer: QW Research is provided for informational and educational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Data is derived from public SEC 13F filings and may be incomplete, delayed, or inaccurate. Do not make investment decisions based on this content. QW Research does not share in any profits and accepts no liability for any losses or decisions made using this information. Past performance does not predict future results.

QW Research © 2026

GSK — Fundamentals, Valuation & Ownership | QW Research

Back to Markets

GSK PLC (GSK)

Highly Crowded

Held by 985 of 5,944 reporting institutions (99th percentile) — extremely crowded.

Data as of Q1 2026

Loading snapshot...

Loading financials...

Loading valuation...

Loading quality & risk...

Loading dividends & returns...

Loading capital allocation...

Loading debt & leverage...

Loading performance...

Loading peer comparison...

Loading ownership map...

Loading crowding analysis...

Loading conviction analysis...

Institutional Ownership

—

of shares outstanding · 985 funds hold it

Ownership Change

—

vs last quarter

Crowding

99ᵗʰ pctl

more crowded than 99% of tracked stocks

Institutional Value

$18.2B

total position value across all 13F filers

Loading buy/sell flow...

Loading ownership trends...

Loading top holders...

Institutional Holders

Loading top holders...

No sector peer set for this ticker (missing sector classification, or too few peers with collected financials).

Institutional Trends (8 Quarters)

No trend data available for this metric.

Ownership Map

The ownership map is taking longer than usual to load. Refresh in a moment — the crowding and activity cards below are ready now.

No collected fundamentals to build a valuation model.

No collected fundamentals for a quality & risk analysis.

No collected fundamentals for a dividends & returns analysis.

No collected fundamentals for a capital-allocation analysis.

No collected fundamentals for a debt & leverage analysis.

Loading ownership map...

Loading crowding analysis...

Ownership Map

The ownership map is taking longer than usual to load. Refresh in a moment — the crowding and activity cards below are ready now.

Crowding AnalysisHighly Crowded

Holders985of 5,944

Avg: 68

Uncrowded99th percentileCrowded

Crowding AnalysisHighly Crowded

Holders985of 5,944

Avg: 68

Uncrowded99th percentileCrowded

Performance vs. S&P 500

Total return (dividends reinvested) vs the market, from quarter-end prices.

$10,000 invested 2021-06

$16,176

GSK · +62%

$18,666

S&P 500 · +87%

−$2,490

behind the index

Total return (5Y)

+62%

S&P 500

+87%

vs. market

-25%

underperformed

Annualized

10.1%

mkt 13.3%

Volatility

25%

annualized

Beta

0.36

vs S&P 500

Growth of $10,000

Hover the chart to read any quarter

GSKS&P 500

Year by year

Annual return vs the market

Hover a year to compare.

GSK (solid)S&P 500 (outline)Green = positive year, red = negative. Number = GSK's return.

Beat the market

3 / 6 yrs

50% win rate

Best year

+51%

2025

Worst year

-17%

2022

Worst drawdown

-32%

recovered in 6 qtrs

Relative strength

Cumulative lead over the S&P 500

Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.

Downside

Drawdown from peak · max -32%

How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.

Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.